Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−4.77 USD
−12.47 M USD
0.00 USD
3.00 M
About NeuroBo Pharmaceuticals, Inc.
Sector
Industry
CEO
Hyung-Heon Kim
Website
Headquarters
Cambridge
Founded
2014
FIGI
BBG009YPPXR8
NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing multi-modal disease-modifying therapies. Its pipeline includes ANA001, a proprietary oral niclosamide formulation, Gemcabene, which is assessed as an acute indication for COVID-19, NB-01, a treatment for painful diabetic neuropathy, and NB-02, which has the potential to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases. The company was founded on October 30, 2014 and is headquartered in Cambridge, MA.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of NRBO is 2.42 USD — it has increased by 0.85% in the past 24 hours. Watch NeuroBo Pharmaceuticals, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange NeuroBo Pharmaceuticals, Inc. stocks are traded under the ticker NRBO.
NRBO stock has fallen by −3.66% compared to the previous week, the month change is a −17.71% fall, over the last year NeuroBo Pharmaceuticals, Inc. has showed a −29.65% decrease.
We've gathered analysts' opinions on NeuroBo Pharmaceuticals, Inc. future price: according to them, NRBO price has a max estimate of 48.00 USD and a min estimate of 10.00 USD. Watch NRBO chart and read a more detailed NeuroBo Pharmaceuticals, Inc. stock forecast: see what analysts think of NeuroBo Pharmaceuticals, Inc. and suggest that you do with its stocks.
NRBO reached its all-time high on Aug 1, 2017 with the price of 129,540.00 USD, and its all-time low was 0.60 USD and was reached on Oct 22, 2014. View more price dynamics on NRBO chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
NRBO stock is 7.14% volatile and has beta coefficient of 1.73. Track NeuroBo Pharmaceuticals, Inc. stock price on the chart and check out the list of the most volatile stocks — is NeuroBo Pharmaceuticals, Inc. there?
Today NeuroBo Pharmaceuticals, Inc. has the market capitalization of 20.42 M, it has increased by 5.86% over the last week.
Yes, you can track NeuroBo Pharmaceuticals, Inc. financials in yearly and quarterly reports right on TradingView.
NeuroBo Pharmaceuticals, Inc. is going to release the next earnings report on Mar 27, 2025. Keep track of upcoming events with our Earnings Calendar.
NRBO earnings for the last quarter are −0.55 USD per share, whereas the estimation was −0.82 USD resulting in a 32.93% surprise. The estimated earnings for the next quarter are −0.49 USD per share. See more details about NeuroBo Pharmaceuticals, Inc. earnings.
NeuroBo Pharmaceuticals, Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
NRBO net income for the last quarter is −5.65 M USD, while the quarter before that showed −10.05 M USD of net income which accounts for 43.78% change. Track more NeuroBo Pharmaceuticals, Inc. financial stats to get the full picture.
No, NRBO doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 26, 2024, the company has 8.00 employees. See our rating of the largest employees — is NeuroBo Pharmaceuticals, Inc. on this list?
Like other stocks, NRBO shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade NeuroBo Pharmaceuticals, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So NeuroBo Pharmaceuticals, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating NeuroBo Pharmaceuticals, Inc. stock shows the sell signal. See more of NeuroBo Pharmaceuticals, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.